Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Traws PharmaTRAW -3.14%41 3-Year EBITDA Growth Rate is 55.10% as of Jun. 2026, which is 16% below its 10-year median of 65.50. GuruFocus rates TRAW with a GF Score™ of 41/100 and a GF Value™ of $9.29 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,130 Biotechnology companies, Traws Pharma ranks better than 88.5% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 55.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 39.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Traws Pharma was 83.90% per year. The lowest was 13.20% per year. And the median was 65.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Traws Pharma 3-Year EBITDA Growth Rate Related Terms
TRAW vs CNSP, MTVA, LIMN: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Traws Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traws Pharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Traws Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Traws Pharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 55.10% mean?
Traws Pharma (TRAW) has a 3-Year EBITDA Growth Rate of 55.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Traws Pharma and its competitors. This is 16% below median its historical median of 65.50. Over the past decade, Traws Pharma's 3-Year EBITDA Growth Rate has ranged from 13.20 to 83.90. According to the industry distribution chart, Traws Pharma ranks #130 out of 1130 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Traws Pharma's 3-Year EBITDA Growth Rate too high?
Traws Pharma's current 3-Year EBITDA Growth Rate of 55.10% is 16% below median its 10-year median of 65.50. Over the past 10 years, this metric has ranged from a low of 13.20 to a high of 83.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Traws Pharma's value of 55.10% is 269.8% above this industry median. Based on the distribution chart, Traws Pharma ranks #130 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Traws Pharma has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's 3-Year EBITDA Growth Rate compare to CNSP and MTVA?
According to the Biotechnology industry distribution chart, Traws Pharma ranks #130 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Traws Pharma in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Traws Pharma's value of 55.10% is 269.8% above this benchmark. Historically, Traws Pharma's own 3-Year EBITDA Growth Rate has ranged from 13.20 to 83.90 over the past decade. While the company's 10-year median is 65.50 vs. the industry median of 14.90, Traws Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Traws Pharma's current 3-Year EBITDA Growth Rate of 55.10% is 269.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Traws Pharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Traws Pharma's current 3-Year EBITDA Growth Rate is 55.10%, which is 16% below median its own 10-year median of 65.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Based on GuruFocus' analysis, Traws Pharma (TRAW) is currently considered Possible Value Trap. The stock's GF Value™ is $9.29, compared to a current price of $0.59 — trading 93.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 55.10%, which is 16% below median its 10-year median of 65.50 and 269.8% above the Biotechnology industry median of 14.90. Traws Pharma's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Traws Pharma (TRAW), the current 3-Year EBITDA Growth Rate is 55.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Traws Pharma (TRAW) Overvalued in 2026?
Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued.
The current stock price of $0.59 is trading 93.7% below its estimated GF Value™ of $9.29.
GuruFocus considers Traws Pharma to be Possible Value Trap.
Key valuation signals for TRAW:
3-Year EBITDA Growth Rate: 55.10% (16% below median its 10-year median of 65.50)
GF Value™: $9.29 vs. price of $0.59 (93.7% below fair value)
Industry Position: 269.8% above the Biotechnology median (#130 of 1130)
No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
41GF Score
Get the complete analysis for TRAW
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRAW has been successfully added to your 
